Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accutane SMART Program Redundancy Is Key To Compliance – Roche

Executive Summary

The redundancy built in to Roche's Accutane SMART risk management program is a key component in ensuring physician compliance, Roche VP-Medical Affairs Russell Ellison, MD, said May 16

You may also be interested in...



PDUFA III Includes Risk Management Fees For “Peri-Approval” Phase

The FDA/industry PDUFA III agreement includes funding to expand FDA's Office of Drug Safety by 100 full-time equivalent staff positions over five years

Pfizer “Toolkit” Proposal Focuses On Adverse Event Signals

Pfizer is proposing that the PhRMA/FDA "toolkit" working group focus on methods to gather more reliable signals of adverse events as a precursor to an improved risk management system

Roche Accutane Prescriber Registry Added To Pregnancy Prevention Program

Accutane prescribers must register with Roche to receive "qualification stickers" under the company's updated pregnancy prevention program

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel